

NASDAQ: IDYA
March 2021

IDEAYA Biosciences

Improving Lives
Through Transformative
Precision Medicines

IDEAYA Highlights

Breakthrough Science on transformative programs in Synthetic Lethality – an emerging area of precision medicine

Broad Pipeline of potential *first-in-class* precision medicine oncology programs with defined patient biomarkers

Proven Management Team with deep business and scientific experience has built leading oncology companies

Pharma Strategic Partnerships with GlaxoSmithKline¹, including ~\$3 billion in potential cash milestones, and Pfizer²

Strong Balance Sheet of ~\$325 million³ with capital efficient model anticipated to fund operations into 2024

Analyst Coverage by JP Morgan, Citi, Guggenheim, Jefferies, Oppenheimer, Northland, Roth Capital Partners, HC Wainwright and Wedbush

(1) GSK Collaboration, Option and License Agreement

(2) Pfizer Clinical Trial Collaboration and Supply Agreement

(3) Includes \$283.6 million cash, equivalents and marketable securities as of 12/31/2020 plus subsequent \$43.3 million gross ATM proceeds

